Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma
Open Access
- 21 July 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diagnostic Pathology
- Vol. 6 (1), 67
- https://doi.org/10.1186/1746-1596-6-67
Abstract
Distinguishing urothelial carcinoma (UC) from prostate carcinoma (PC) is important due to potential therapeutic and prognostic implications. However, this can be a diagnostic challenge when there is limited tissue and in poorly differentiated tumors. We evaluated the diagnostic utility of a dual immunohistochemical stain comprising p63 and P501S (prostein), applied sequentially on a single slide and visualized by double chromogen reaction, in differentiating these two cancers. Thus far, there have been no previous studies assessing the diagnostic utility of p63 and P501S combined together as a dual immunostain in distinguishing between these two cancers. p63/P501S dual-color sequential immunohistochemical staining was performed on archival material from 132 patients with high-grade UC and 23 patients with PC, and evaluated for p63 (brown nuclear) and P501S (red cytoplasmic) expression. Both the staining intensity and percentage of positive tumor cells were assessed. p63 was positive in 119/132 of UC and negative in PC. P501S was positive in 22/23 of PC and negative in UC. The p63+/P501S- immunoprofile had 90% sensitivity and 100% specificity for UC. The p63-/P501S+ immunoprofile had 96% sensitivity and 100% specificity for PC. Our results indicate that double sequential immunohistochemical staining with p63 and P501S is highly specific and can be a useful tool in distinguishing UC from PC especially when there is limited diagnostic tissue as it can be performed on a single slide.Keywords
This publication has 22 references indexed in Scilit:
- The role of P63 in cancer, stem cells and cancer stem cellsCellular & Molecular Biology Letters, 2011
- Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinomaDiagnostic Pathology, 2007
- The Role of P501S and PSA in the Diagnosis of Metastatic Adenocarcinoma of the ProstateThe American Journal of Surgical Pathology, 2007
- Immunohistochemical Differentiation of High-grade Prostate Carcinoma From Urothelial CarcinomaThe American Journal of Surgical Pathology, 2007
- Placental S100 (S100P) and GATA3: Markers for Transitional Epithelium and Urothelial Carcinoma Discovered by Complementary DNA MicroarrayThe American Journal of Surgical Pathology, 2007
- Prostate-Specific Antigen, High-Molecular-Weight Cytokeratin (Clone 34βE12), and/or p63American Journal of Clinical Pathology, 2006
- Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literatureHistopathology, 2005
- Prostein expression is highly restricted to normal and malignant prostate tissuesThe Prostate, 2004
- Immunophenotypic Characterization of 225 Prostate Adenocarcinomas With Intermediate or High Gleason ScoresAmerican Journal of Clinical Pathology, 2002
- Uroplakin III Is a Highly Specific and Moderately Sensitive Immunohistochemical Marker for Primary and Metastatic Urothelial CarcinomasAmerican Journal of Clinical Pathology, 2000